News and Announcements
Atomo Diagnostics – CEO Interview
- Published October 27, 2015 6:09PM UTC
- Publisher Wholesale Investor
- Categories Executive Interviews
Atomo Diagnostics is a multi-award winning and rapidly growing medical device company that has developed and commercialised AtomoRapid™, the world’s first integrated device for blood based immunoassay rapid diagnostic testing (RDTs) in point of care settings.
Atomo launched its first test on the platform, AtomoRapid HIV, in 2014. Since launch, AtomoRapid tests have quickly established themselves as a “best in class” solution for professional use diagnostic screening.
With tests now commercialised for HIV and malaria and a rapid Ebola test ready for launch later this year, Atomo is disrupting global RDT markets where convenience, usability and safety have for many years been largely overlooked.
Please listen to John Kelly, CEO of Atomo Diagnostics below.
Executive Interviews
Following the Billions: Where the Hyperscalers are Betting on the Future
The roadmap for the next decade isn’t hidden in pitch decks—it’s written on the balance sheets of Microsoft, Amazon, and Google. Their collective investment is flowing into three key areas: GPU Chips, AI Factories, and Energy. This foundational buildout signals a $7–$20 trillion economic convergence, where the physical race for infrastructure and energy is paramount. The article also covers the powerful macro case for digital assets in this new era.
The Great Re-Allocation: Why AI is Forcing Smart Money From Software to Hard Science
Smart money is rapidly shifting its investment focus from commoditized software to hard science and deep tech, as AI dissolves traditional software moats. Discover the dual pressure on investors and the pivot to businesses with durable, real-world defensive barriers.
AI is The Cheapest, Highest-Leverage Investment You Will Ever Make
AI tools offer a 10x productivity increase for a minimal monthly cost, making them the highest-ROI investment in business today. However, this massive potential remains dormant. The real opportunity is not in owning the tools, but in having the strategic playbook to deploy them organization-wide and build a defensible competitive advantage.
Backed By Leading Investment Groups and Family Offices
